<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04110886</url>
  </required_header>
  <id_info>
    <org_study_id>HSK21542-101</org_study_id>
    <nct_id>NCT04110886</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of HSK21542 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of a Kappa Receptor Agonist HSK21542 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Haisco Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CMAX Clinical Research Pty Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sichuan Haisco Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose
      Study To Investigate the Safety, Tolerability, and Pharmacokinetics of a kappa receptor
      agonist HSK21542 in Healthy Volunteers.

      The study will enroll approximately 50 adults. The anticipated study duration will be up to 6
      months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2019</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>Between screening and 7-9 days after dosing</time_frame>
    <description>To evaluate the safety and tolerability of HSK21542 in comparison with placebo after a single injection in healthy subjects in terms of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal physical examination/ abnormal vital signs/ abnormal laboratory parameters</measure>
    <time_frame>Between screening and 7-9 days after dosing</time_frame>
    <description>To evaluate the safety and tolerability of HSK21542 in comparison with placebo after a single injection in healthy subjects in terms of abnormal physical examination/ abnormal vital signs/ abnormal laboratory parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>From the start of administration to 24 hours after administration</time_frame>
    <description>Maximum (peak) plasma drug concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>From the start of administration to 24 hours after administration</time_frame>
    <description>Time to reach maximum (peak) plasma concentration following drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>From the start of administration to 24 hours after administration</time_frame>
    <description>Elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>From the start of administration to 24 hours after administration</time_frame>
    <description>Area under the plasma concentration-time curve from time zero to time t.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf</measure>
    <time_frame>From the start of administration to 24 hours after administration</time_frame>
    <description>Area under the plasma concentration-time curve from time zero to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL</measure>
    <time_frame>From the start of administration to 24 hours after administration</time_frame>
    <description>Apparent total body clearance of the drug from plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd</measure>
    <time_frame>From the start of administration to 24 hours after administration</time_frame>
    <description>Apparent volume of distribution</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Postoperative Pain</condition>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>HSK21542 single ascending doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK21542</intervention_name>
    <description>Single dose, injection, starting dose of 0.2ug escalating up to 20ug</description>
    <arm_group_label>HSK21542 single ascending doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose, injection matching placebo</description>
    <arm_group_label>Placebo single dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects, age 18-45 years;

          -  BMI between 18.0-27.0 kg/m2

          -  Determined by investigator to be in general good health according to medical history,
             comprehensive physical examination;

          -  Understanding of the nature, significance, potential benefits and risks of the trial,
             understanding of the procedures and be able to provide written informed consent
             voluntarily ;

          -  Good communication with investigators, compliance with the study requirements and
             willingness to stay in phase I clinical trial ward as required.

        Exclusion Criteria:

          -  Anyone who has suffered or is currently suffering from any serious diseases, that may
             interfere with the results of the trial;

          -  Determined by investigator to be abnormal with clinical significance in Physical
             examination, vital signs monitoring, electrocardiogram, chest radiograph, laboratory
             examination;

          -  HBsAg positive, HCV antibody positive, Treponema pallidum antibody positive, or HIV
             antibody positive;

          -  QTcF &gt; 450ms;

          -  Allergic constitution;

          -  Intolerance of venipuncture and/or history of haemorrhage or needle fainting;

          -  Drug or alcohol abuse;

          -  Have used any prescription, over-the-counter, Chinese herbal medicine or health
             products within 14 days;

          -  Blood donation or massive bleeding within 3 months (greater than 450 mL);

          -  Participants in any drug clinical trial within 3 months.

          -  Birth planning in the next six months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Wabnitz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CMAX Clinical Research Pty Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>zhenghong Xia</last_name>
    <phone>86</phone>
    <phone_ext>18964573960</phone_ext>
    <email>xiazhenghong@haisco.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CMAX Clinical Research Pty Ltd</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuliang Li</last_name>
      <phone>181 8069 7260</phone>
      <email>lixuliang@haisco.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 27, 2019</study_first_submitted>
  <study_first_submitted_qc>September 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2019</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Postoperative Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

